8 August 2022, 07:30, Adelaide, Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce that the US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) vaginal hormonal contraceptive ring. Mayne Pharma anticipates the commercial launch of HALOETTE® ring by early calendar year 2023.
https://www.mithra.com/wp-content/uploads/2019/09/USA-flag.jpg 1282 1920 Célia Berlemont https://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.png Célia Berlemont2022-08-08 07:30:552022-08-07 22:14:37Mayne Pharma and Mithra announce FDA approval of HALOETTE®, a generic version of NUVARING®
Rue Saint-Georges 5
Tel. : +32 (0)4 349 28 22
Fax : +32 (0)4 349 28 21
Email : firstname.lastname@example.org